Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two-centre Australian experience

Jeremy Er; David Routledge; Jennifer Hempton; Colin Wood; Trish Joyce; Simon Harrison; Philip Campbell

doi:10.1111/imj.15182

Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two-centre Australian experience

Intern Med J. 2021 Feb;51(2):280-283. doi: 10.1111/imj.15182.

Authors

Jeremy Er^{1

2}, David Routledge^{1

2

3}, Jennifer Hempton¹, Colin Wood², Trish Joyce², Simon Harrison^{2

3}, Philip Campbell^{1

4}

Affiliations

¹ University Hospital Geelong, Barwon Health, Geelong, Victoria, Australia.
² Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
³ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
⁴ Deakin University, Geelong, Victoria, Australia.

PMID: 33631863
DOI: 10.1111/imj.15182

Abstract

There are currently limited Australian data on the outcomes of autologous stem cell transplantation (ASCT) in elderly multiple myeloma (MM) patients. We present the largest cohort of elderly MM patients aged ≥65 years undergoing ASCT in Australia and report their outcomes based on our two-centre experience. Our study affirms that ASCT is well tolerated, safe and effective in elderly MM patients aged ≥65 years and should be considered an important component of treatment in patients who are fit enough for the procedure.

Keywords: myeloma, elderly, autologous stem cell transplant, outcomes.

MeSH terms

Aged
Australia / epidemiology
Hematopoietic Stem Cell Transplantation*
Humans
Multiple Myeloma* / epidemiology
Multiple Myeloma* / therapy
Retrospective Studies
Stem Cell Transplantation
Transplantation, Autologous
Treatment Outcome